Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Nanostructured lipid carriers can improve alopecia treatment by enhancing drug delivery and promoting hair growth.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This study found that the genetic variants rs231775 and rs3087243 of the CTLA4 gene are not associated with alopecia areata in the Mexican population analyzed.

This article discusses various methods, including Skincell Advanced and Mesoderm youth activator cream, for improving skin appearance and reducing signs of aging but reports no new research findings.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

This study identified a new heterozygous mutation in the connexin 26 gene (c.263C>T; p.Ala88Val) in a premature neonate with KID syndrome, who later died from complications.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

In this mouse study, researchers found that nanoparticles loaded with umbilical cord-derived stem cell membranes and minoxidil enhanced hair growth by improving drug solubility and transdermal delivery, increasing VEGF, IGF-1, MKI67, and CTNNB protein levels in skin tissue compared to regular minoxidil.

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

This study found that a new treatment candidate may effectively prevent and promote recovery from chemotherapy-induced alopecia by normalizing apoptosis and reducing inflammation in cancer patients.

This research investigates apoptosis and bcl 2 expression in hair follicles cultured with and without biotin, but it reports no new results.

This study suggests that dsRNA may enhance KRT9 expression in palm and sole skin through β-catenin signaling, potentially linking mechanical damage to specific skin features and certain skin conditions.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

In this study, researchers observed significant clinical improvement and patient satisfaction in the treatment of androgenic alopecia with a 1927-nm thulium laser, noting no adverse events and minimal pain across a short-term evaluation of ten patients.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

In this study, researchers identified a recurrent MBTPS2 splice-site variant as a mutational hotspot in IFAP syndrome across diverse families, with phenotype severity suggesting the influence of additional modifiers.

This placebo-controlled study found that topical procyanidin B2 significantly increased total and anagen hair counts in men with androgenetic alopecia over 16 weeks compared to placebo, suggesting it as an effective and safe treatment option.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.